المؤلفون: S. К. Zyryanov, I. N. Dyakov, С. К. Зырянов, И. Н. Дьяков

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 17, No 1 (2024); 22-29 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 17, No 1 (2024); 22-29 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: анализ влияния на бюджет, NSCLC, combination therapy, immunotherapy drugs, platinum-containing chemotherapy, cost minimization analysis, budget impact analysis, НМРЛ, комбинированная терапия, иммунотерапевтические препараты, платиносодержащая химиотерапия, анализ минимизации затрат

وصف الملف: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/1005/524; Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2023: 239 с.; Злокачественное новообразование бронхов и легкого. Клини- ческие рекомендации. 2022. URL: https://cr.minzdrav.gov.ru/recomend/30_4 (дата обращения 29.01.2024).; Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394–424. https://doi.org/10.3322/caac.21492.; Low J.L., Walsh R.J., Ang Y., et al. The evolving immunooncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Ther Adv Med Oncol. 2019; 11: 1758835919870360. https://doi.org/10.1177/1758835919870360.; Herbst R.S., Morgensztern D., Boshoff C. The biology and mana- gement of nonsmall cell lung cancer. Nature. 2018; 553 (7689): 446– 54. https://doi.org/10.1038/nature25183.; Gravara L.D., Battiloro C., Cantile R., et al. Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? Lung Cancer Manag. 2020; 9 (1): LMT22. https://doi.org/10.2217/lmt-2019-0018.; Gandhi I., Rodíguez-Abreu D., Gadgeel S., et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018; 378 (22): 2078–92. https://doi.org/10.1056/NEJMoa1801005.; Lala M., Li T.R., de Alwis D.P., et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020; 131: 68–75. https://doi.org/10.1016/j.ejca.2020.02.016.; Socinski M.A., Jotte R.M., Cappuzzo F., et al. Atezolizumab in firstline treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018; 378 (24): 2288–301. https://doi.org/10.1056/NEJMoa1716948.; Инструкция по медицинскому применению препарата Тецентрик®. Государственный реестр лекарственных средств. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dc5d11e8-01a54a51-831c-40333a790f57 (дата обращения 29.01.2024).; Инструкция по медицинскому применению препарата Пемброриа®. Государственный реестр лекарственных средств. URL; https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3976dcd1-ee064c96-a077-c4fd2979c9a9 (дата обращения 29.01.2024).; Инструкция по медицинскому применению препарата Авастин®. Государственный реестр лекарственных средств. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=bd34de45-7603-42abbbd8-21144149bb98 (дата обращения 29.01.2024).; Halmos B., Burke T., Kalyvas C., et al. Pembrolizumab + chemo- therapy versus atezolizumab + chemotherapy ± bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison. Lung Cancer. 2021; 155: 175–82. https://doi.org/10.1016/j.lungcan.2021.03.020.; Государственный реестр предельных отпускных цен. URL: https://grls.rosminzdrav.ru/pricelims.aspx (дата обращения 29.01.2024).; Методические рекомендации по оценке влияния на бюджет в рамках реализации программы государственных гарантий бесплатного оказания гражданам медицинской помощи. М.: ФГБУ «ЦЭККМП»; 2016: 27 с.; Reck M., Rodríguez-Abreu D., Robinson A.G., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375 (19): 1823–33. https://doi.org/10.1056/NEJMoa1606774.; Gandhi L., Rodríguez-Abreu D., Gadgeel S., et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018; 378 (22): 2078–92. https://doi.org/10.1056/NEJMoa1801005.; Зырянов С.К., Дьяков И.Н. Обновленный фармакоэкономический анализ эффективности применения препарата атезолизумаб в сравнении с другими ингибиторами PD-1 у пациентов с распространенным немелкоклеточным раком легкого после предшествующей химиотерапии. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2023; 16 (3): 422–30. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.211.; Créquit P., Chaimani A., Yavchitz A., et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC Med. 2017; 15 (1): 193. https://doi.org/10.1186/s12916-017-0954-x.; https://www.pharmacoeconomics.ru/jour/article/view/1005

الاتاحة: https://www.pharmacoeconomics.ru/jour/article/view/1005
https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.242

المؤلفون: S. K. Zyryanov, I. N. Dyakov, С. К. Зырянов, И. Н. Дьяков

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 16, No 3 (2023); 422-430 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 16, No 3 (2023); 422-430 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: анализ влияния на бюджет, NSCLC, second line therapy, third line therapy, checkpoint inhibitors, PD-1/PD-L1 inhibitors, atezolizumab, pembrolizumab, nivolumab, cost minimization analysis, budget impact analysis, НМРЛ, вторая линия терапии, третья линия терапии, ингибиторы контрольных точек, ингибиторы PD-1/PD-L1, атезолизумаб, пембролизумаб, ниволумаб, анализ минимизации затрат

وصف الملف: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/894/498; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022: 239 с.; Злокачественное новообразование бронхов и легкого. Клинические рекомендации. 2022. URL: https://cr.minzdrav.gov.ru/recomend/30_4 (дата обращения 03.09.2023).; Инструкция по медицинскому применению лекарственного препарата Китруда®. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=88450c76-24e5-43ee-bbd3-afd10dc1e7c8&t= (дата обращения 03.09.2023).; Инструкция по медицинскому применению лекарственного препарата Опдиво® URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f6ac1a6a-9f33-4eaa-a603-b2928d720378&t= (дата обращения 03.09.2023).; Инструкция по медицинскому применению лекарственного препарата Тецентрик®. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c210e8ba-5f80-4dc6-90bc-98e51fb468ed&t= (дата обращения 03.09.2023).; Зырянов С.К., Дьяков И.Н. Фармакоэкономическая эффективность применения препарата атезолизумаб в сравнении с другими ингибиторами PD-1 у пациентов с распространенным немелкоклеточным раком легкого после предшествующей химиотерапии. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (1): 5–12. https://doi.org/10.17749/20704909.2020.13.1.5-12.; Créquit P., Chaimani A., Yavchitz A., et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC Med. 2017; 15 (1): 193. https://doi.org/10.1186/s12916-017-0954-x.; Rittmeyer A., Barlesi F., Waterkamp D., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389 (10066): 255–65. https://doi.org/10.1016/S01406736(16)32517-X.; НМИЦ oнкологии им. Н.Н. Блохина. Прейскурант. URL: https://www.ronc.ru/platnye-uslugi/prays-list-uslug/ (дата обращения 03.09.2023).; Постановление Правительства РФ от 28.08.2014 № 871 «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». URL: https://base.garant.ru/70728348/ (дата обращения 03.09.2023).; https://www.pharmacoeconomics.ru/jour/article/view/894

الاتاحة: https://www.pharmacoeconomics.ru/jour/article/view/894
https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.211

المؤلفون: A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina, А. C. Колбин, Ю. М. Гомон, М. А. Проскурин, Ю. Е. Балыкина

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 16, No 3 (2023); 412-421 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 16, No 3 (2023); 412-421 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: анализ минимизации затрат, NSCLC, targeted therapy, alectinib, lorlatinib, pharmacoeconomic analysis, cost minimization analysis, НМРЛ, таргетная терапия, алектиниб, лорлатиниб, клинико-экономический анализ

وصف الملف: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/893/497; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022: 252 с.; Злокачественное новообразование бронхов и легкого. Клинические рекомендации. 2022. URL: https://cr.minzdrav.gov.ru/recomend/30_4 (дата обращения 30.08.2023).; Arbour K.C., Riely G.J. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019; 322 (8): 764–74. https://doi.org/10.1001/jama.2019.11058.; Jordan E.J., Kim H.R., Arcila M.E., et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017; 7 (6): 596–609. https://doi.org/10.1158/2159-8290.CD-16-1337.; Лактионов К.К., Артамонова Е.В., Бредер В.В., и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2022; 12 (3s2-1): 41–59. https://doi.org/10.18027/2224-5057-2022-12-3s2-41-59.; Ando K., Manabe R., Kishino Y., et al. Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced nonsmall cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis. Cancers (Basel). 2021; 13 (15): 3704. https://doi.org/10.3390/cancers13153704.; Единая информационная система в сфере закупок. URL: https://zakupki.gov.ru/epz/main/public/home.html (дата обращения 30.08.2023).; Инструкция по медицинскому применению препарата Лорвиква®. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=65a7f3ed-650d-4ce9-9d7d-1444a0147690 (дата обращения 30.08.2023).; Инструкция по медицинскому применению препарата Алеценза®. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=85023a03-a0a7-4e27-9af6-f3102e10ac80 (дата обращения 30.08.2023).; Постановление Правительства РФ от 29.12.2022 № 2497 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2023 год и на плановый период 2024 и 2025 годов». URL: https://base.garant.ru/406065459/ (дата обращения 30.08.2023).; Методические рекомендации по способам оплаты медицинской помощи за счет средств обязательного медицинского страхования (утв. Министерством здравоохранения РФ и Федеральным фондом обязательного медицинского страхования 02.02.2022, №№ 11-7/И/2-1619, 00-10-26-2-06/750). URL: https://www.garant.ru/products/ipo/prime/doc/403402448/ (дата обращения 30.08.2023).; Peters S., Camidge D.R., Shaw A.T. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017; 377 (9): 829–38. https://doi.org/10.1056/NEJMoa1704795.; Shaw A.T., Bauer T.M., de Marinis F., et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020; 383 (21): 2018–29. https://doi.org/10.1056/NEJMoa2027187.; https://www.pharmacoeconomics.ru/jour/article/view/893

الاتاحة: https://www.pharmacoeconomics.ru/jour/article/view/893
https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.210

المؤلفون: E. A. Lukbanova, E. A. Dzhenkova, A. S. Goncharova, A. Yu. Maksimov, E. F. Komarova, V. I. Minkin, Yu. A. Sayapin, E. A. Gusakov, L. Z. Kurbanova, A. A. Kiblitskaya, E. V. Zaikina, M. V. Mindar, M. V. Voloshin, A. V. Shaposhnikov, I. B. Lysenko, N. V. Nikolaeva, Е. А. Лукбанова, Е. А. Дженкова, А. С. Гончарова, А. Ю. Максимов, Е. Ф. Комарова, В. И. Минкин, Ю. А. Саяпин, Е. А. Гусаков, Л. З. Курбанова, А. А. Киблицкая, Е. В. Заикина, М. В. Миндарь, М. В. Волошин, А. В. Шапошников, И. Б. Лысенко, Н. В. Николаева

المساهمون: The studied compound was synthesized as part of implementation of the SSC RAS State task No. 01201354239, with financial support of the Ministry of Science and Higher Education of the Russian Federation (State task in science, project No. 0852-2020-0031). Studies in vivo were performed as part of the State task No. 121031100253-3 “Study of antitumor activity of pharmacological substances in vivo and in vitro”., Синтез исследуемого соединения осуществляли в рамках реализации Государственного задания ЮНЦ РАН № 01201354239 при финансовой поддержке Министерства науки и высшего образования Российской Федерации (Государственное задание в области научной деятельности, проект № 0852-2020-0031). Исследования in vivo проводили в рамках государственного задания № 121031100253-3 «Изучение противоопухолевой активности фармакологических субстанций in vivo и in vitro».

المصدر: Research and Practical Medicine Journal; Том 9, № 2 (2022); 50-64 ; Research'n Practical Medicine Journal; Том 9, № 2 (2022); 50-64 ; 2410-1893 ; 2409-2231 ; 10.17709/2410-1893-2022-9-2

مصطلحات موضوعية: немелкоклеточный рак легкого (НМРЛ), antitumor activity, Balb/c Nude mice, xenograft, dose dependent effects, toxic effect, non-small-cell lung carcinoma (NSCLC), противоопухолевая активность, мыши линии Balb/c Nude, ксенографт, дозозависимые эффекты, токсическое влияние

وصف الملف: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/743/482; https://www.rpmj.ru/rpmj/article/downloadSuppFile/743/532; https://www.rpmj.ru/rpmj/article/downloadSuppFile/743/533; Кит О. И., Франциянц Е. М., Меньшенина А. П., Моисеенко Т. И., Ушакова Н. Д., Попова Н. Н. и др. Роль плазмофереза и ксенонтерапии в коррекции острых последствий хирургической менопаузы у больных раком шейки матки. Политематический сетевой электронный научный журнал Кубанского государственного аграрного университета. 2016;(117):472–486.; Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. https://doi.org/10.3322/caac.21492; National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer. 2019. Доступно по: https://seer.cancer.gov/statfacts/html/lungb.html, Дата обращения: 23.03.2022.; Gonzalez‑Rajal A, Hastings JF, Watkins DN, Croucher DR, Burgess A. Breathing New Life into the Mechanisms of Platinum Resistance in Lung Adenocarcinoma. Front Cell Dev Biol. 2020;8:305. https://doi.org/10.3389/fcell.2020.00305; Бурнашева Е. В., Шатохин Ю. В., Снежко И. В., Мацуга А. А. Поражение почек при противоопухолевой терапии. Нефрология. 2018;22(5):17–24. https://doi.org/10.24884/1561‑6274‑2018‑22‑5‑17‑24; Kit OI, Shikhlyarova AI, Maryanovskaya GY, Barsukova LP, Kuzmenko TS, Zhukova GV, et al. Theory of health: successful translation into the real life. General biological prerequisites. Cardiometry. 2015;(7):11–17. https://doi.org/10.12710/cardiometry.2015.7.1117; Haney SL, Allen C, Varney ML, Dykstra KM, Falcone ER, Colligan SH, et al. Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. Oncotarget. 2017 Sep 29;8(44):76085–76098. https://doi.org/10.18632/oncotarget.18543; Zhang G, He J, Ye X, Zhu J, Hu X, Shen M, et al. β‑Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS‑mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. Cell Death Dis. 2019 Mar 15;10(4):255. https://doi.org/10.1038/s41419‑019‑1492‑6; Maldonado EN, Patnaik J, Mullins MR, Lemasters JJ. Free tubulin modulates mitochondrial membrane potential in cancer cells. Cancer Res. 2010 Dec 15;70(24):10192–10201. https://doi.org/10.1158/0008‑5472.CAN‑10‑2429; Kurek J, Kwaśniewska‑Sip P, Myszkowski K, Cofta G, Barczyński P, Murias M, et al. Antifungal, anticancer, and docking studies of colchiceine complexes with monovalent metal cation salts. Chem Biol Drug Des. 2019 Sep;94(5):1930–1943. https://doi.org/10.1111/cbdd.13583; Ido Y, Muto N, Inada A, Kohroki J, Mano M, Odani T, et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase‑3. Cell Prolif. 1999 Feb;32(1):63–73. https://doi.org/10.1046/j.1365‑2184.1999.3210063.x; Патент РФ. RU 2741311 C1. Заявка № 2020123736 от 17.07.20 г. Минкин В. И., Кит О. И., Гончарова А. С., Лукбанова Е. А., Саяпин Ю. А., Гусаков Е. А. и др. Средство, обладающее цитотоксической активностью в отношении культуры клеток немелкоклеточного рака легких А 549. Доступно по: https://patenton.ru/patent/RU2741311C1.pdf, Дата обращения: 23.03.2022.; Li L‑H, Wu P, Lee J‑Y, Li P‑R, Hsieh W‑Y, Ho C‑C, et al. Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib‑resistant lung adenocarcinoma cells. PLoS One. 2014;9(8):e104203. https://doi.org/10.1371/journal.pone.0104203; Патент RU № 2712916, опубл. 03.02.2020, Бюл. № 4. Колесников Е. Н., Лукбанова Е. А., Ванжа Л. В., Максимов А. Ю., Кит С. О., Гончарова А. С. и др. Способ проведения наркоза у мышей Balb/c Nude при оперативных вмешательствах. Доступно по: https://patenton.ru/patent/RU2712916C1.pdf, Дата обращения: 23.03.2022.; Трещалина Е. М., Жукова О. С., Герасимова Г. К., Андронова Н. В., Гарин А. М. Методические указания по изучению противоопухолевой активности фармакологических веществ. В кн.: Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Под ред. Хабриева Р. У. М: Медицина, 2005, 637–651 с.; Чибуновский В. А. Интерпретация результатов клинико‑биохимических лабораторных исследований. Алматы, 1998.; Лукбанова Е. А., Заикина Е. В., Саяпин Ю. А., Гусаков Е. А., Филиппова С. Ю., Златник Е. Ю. и др. Оценка противоопухолевого эффекта 2‑(6,8‑диметил‑5‑нитро‑4‑хлорхинолин‑2‑ил)‑5,6,7‑трихлор‑1,3‑трополона на подкожных ксенографтах культуры опухолевых клеток А‑549. Альманах клинической медицины. 2021;49(6):396–404. https://doi.org/10.18786/2072‑0505‑2021‑49‑021; Заборовский А. В., Кокорев А. В., Бродовская Е. П., Фирстов С. А., Минаева О. В., Куликов О. А. и др. Направленная доставка доксорубицина с помощью экзогенных биосовместимых нановекторов при экспериментальных неоплазиях. Вестник Мордовского университета. 2017;27(1):93–107. https://doi.org/10.15507/0236‑2910.027.201701.093‑107; Chen S‑M, Wang B‑Y, Lee C‑H, Lee H‑T, Li J‑J, Hong G‑C, et al. Hinokitiol up‑regulates miR‑494‑3p to suppress BMI1 expression and inhibits self‑renewal of breast cancer stem/progenitor cells. Oncotarget. 2017 Sep 29;8(44):76057–76068. https://doi.org/10.18632/oncotarget.18648; Lee Y‑S, Choi K‑M, Kim W, Jeon Y‑S, Lee Y‑M, Hong J‑T, et al. Hinokitiol inhibits cell growth through induction of S‑phase arrest and apoptosis in human colon cancer cells and suppresses tumor growth in a mouse xenograft experiment. J Nat Prod. 2013 Dec 27;76(12):2195–2202. https://doi.org/10.1021/np4005135; Seo JS, Choi YH, Moon JW, Kim HS, Park S‑H. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017 Feb 27;18(1):14. https://doi.org/10.1186/s12860‑017‑0130‑3; https://www.rpmj.ru/rpmj/article/view/743

الاتاحة: https://www.rpmj.ru/rpmj/article/view/743
https://doi.org/10.17709/2410-1893-2022-9-2-4

المؤلفون: E. S. Denisova, K. K. Laktionov, M. A. Ardzinba, E. V. Reutova, Е. С. Денисова, К. К. Лактионов, М. С. Ардзинба, Е. В. Реутова

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2022); 14-20 ; Медицинский Совет; № 9 (2022); 14-20 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: клинические исследования, adjuvant therapy, immunotherapy, atezolizumab, early stage NSCLC, checkpoint inhibitors, clinical trials, адъювантная терапия, иммунотерапия, атезолизумаб, ранняя стадия НМРЛ, ингибиторы контрольных точек

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6910/6210; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660.; Bareschino M.A., Schettino C., Rossi A., Maione P., Sacco P.C., Zeppa R., Gridelli C. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3(2):122-133. https://doi.org/10.3978/j.issn.2072-1439.2010.12.08.; Vansteenkiste J., Wauters E., Reymen B., Ackermann C.J., Peters S., De Ruysscher D. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol. 2019;30(8):1244-1253. https://doi.org/10.1093/annonc/mdz175.; de Groot P.M., Wu C.C., Carter B.W., Munden R.F. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220-233. https://doi.org/10.21037/tlcr.2018.05.06.; Broderick S.R. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer. Thorac Surg Clin. 2020;30(2):215-220. https://doi.org/10.1016/j.thorsurg.2020.01.001.; Chmielewska I., Stencel K., Kalinka E., Ramlau R., Krawczyk P. Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer-Clinical Trials Experience. Cancers (Basel). 2021;13(20):5048. https://doi.org/10.3390/cancers13205048.; Bradbury P., Sivajohanathan D., Chan A., Kulkarni S., Ung Y., Ellis P.M. Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clin Lung Cancer. 2017;18(3):259-273.e8. https://doi.org/10.1016/j.cllc.2016.07.002.; Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.-P., Vansteenkiste J., International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351-360. https://doi.org/10.1056/NEJMoa031644.; Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C. et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589-2597. https://doi.org/10.1056/NEJMoa043623.; Pignon J.-P., Tribodet H., Scagliotti G.V., Douillard J.-Y., Shepherd F.A., Stephens R.J. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559. https://doi.org/10.1200/JCO.2007.13.9030.; Detterbeck F. What to do with “Surprise” No. 2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol. 2008;3(3):289-302. https://doi.org/10.1097/JTO.0b013e3181630ebd.; Douillard J.-Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719-727. https://doi.org/10.1016/S1470-2045(06)70804-X.; Usami N., Yokoi K., Hasegawa Y., Taniguchi H., Shindo J., Yamamoto M. et al. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol. 2010;15(6):583-587. https://doi.org/10.1007/s10147-010-0118-x.; Zhang L., Ou W., Liu Q., Li N., Liu L., Wang S. Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squa-mous non-small cell lung cancer. Thorac Cancer. 2014;5(1):50-56. https://doi.org/10.1111/1759-7714.12058.; Lim E., Harris G., Patel A., Adachi I., Edmonds L., Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009;4(11):1380-1388. https://doi.org/10.1097/JTO.0b013e3181b9ecca.; Wu Y.-L., Tsuboi M., He J., John T., Grohe C., Majem M. et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(18):1711-1723. https://doi.org/10.1056/NEJMoa2027071.; Vansteenkiste J.F., Cho B.C., Vanakesa T., De Pas T., Zielinski M., Kim M.S. et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822-835. https://doi.org/10.1016/S1470-2045(16)00099-1.; Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W. et al. Adjuvant MAGE-A3 immunotherapy in resected nonsmall-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31(19):2396-2403. https://doi.org/10.1200/JCO.2012.43.7103.; Shakhar G., Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10(8):972-992. https://doi.org/10.1245/aso.2003.02.007.; Espí A., Arenas J., Garda-Granero E., Martí E., Lledó S. Relationship of curative surgery on natural killer cell activity in colorectal cancer. Dis Colon Rectum. 1996;39(4):429-434. https://doi.org/10.1007/BF02054059.; Coffey J.C., Wang J.H., Smith M.J., Bouchier-Hayes D., Cotter T.G., Redmond H.P. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 2003;4(12):760-768. https://doi.org/10.1016/s1470-2045(03)01282-8.; Tai L.H., de Souza C.T., Bélanger S., Ly L., Alkayyal A.A., Zhang J. et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013;73(1):97-107. https://doi.org/10.1158/0008-5472.CAN-12-1993.; Ananth A.A., Tai L.-H., Lansdell C., Alkayyal A.A., Baxter K.E., Angka L. et al. Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated AntiTumor Immunity Leading to Postoperative Cancer Recurrence. PLoS ONE. 2016;11(5):e0155947. https://doi.org/10.1371/journal.pone.0155947.; Sun Z., Mao A., Wang Y., Zhao Y., Chen J., Xu P., Miao C. Treatment with anti-programmed cell death 1 (PD-1) antibody restored postoperative CD8+ T cell dysfunction by surgical stress. Biomed Pharmacother. 2017;89:1235-1241. https://doi.org/10.1016/j.biopha.2017.03.014.; Shi T., Zhu S., Guo H., Li X., Zhao S., Wang Y. et al. The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected NonSmall Cell Lung Cancer: A Meta-Analysis of Literatures. Front Oncol. 2021;11:567978. https://doi.org/10.3389/fonc.2021.567978.; Catania C., Muthusamy B., Spitaleri G., Del Signore E., Pennell N.A. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. Clin Lung Cancer. 2022;23(2):108-115. https://doi.org/10.1016/j.cllc.2021.11.003.; Durm G.A., Furqan M., Feldman L.E., Patel M., Hall R.D., Jalal S.I. et al. A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153. J Clin Oncol. 2021;39(15_suppl):TPS8583-TPS8583. https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS8583.; Ahn M.-J., Park S., Jung H.E., Cho J.H., Sun J.-M., Lee S.-H. et al. Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive nonsmall cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results. J Clin Oncol. 2019;37(15_suppl):8520-8520. https://doi.org/10.1200/JCO.2019.37.15_suppl.8520.; Mielgo-Rubio X., Montemuino S., Jiménez U., Luna J., Cardeña A., Mezquita L. et al. Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy. Cancers (Basel). 2021;13(19):4811. https://doi.org/10.3390/cancers13194811.; Pellini B., Chaudhuri A.A. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. J Clin Oncol. 2022;40(6):567-575. https://doi.org/10.1200/JCO.21.01929.; Soria J.C., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee K.H. et al. Osimertinib in Untreated EGFR-Mutated Advanced NonSmall-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125. https://doi.org/10.1056/NEJMoa1713137.; Shibaki R., Akamatsu H., Kato T., Nishino K., Okada M., Mitsudomi T. et al. A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study). Ther Adv Med Oncol. 2021;13:1758835920987647. https://doi.org/10.1177/1758835920987647.; Kris M.G., Faivre-Finn C., Kordbacheh T., Chaft J., Luo J., Tsao A., Swisher S. Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book. 2020;40:e159-e170. https//doi.org/10.1200/EDBK_280807.; O'Brien M.E.R., Hasan B., Dafni U., Menis J., Peters S., De Waele M. et al. EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372). J Clin Oncol. 2016;34(15_suppl):TPS8571-TPS8571. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS8571.; Calvo V., Domine M., Sullivan I., Gonzalez-Laribba J.-L., Ortega A.L., Bernabe R. et al. A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus. J Clin Oncol. 2021;39(15_suppl):TPS8581-TPS8581. https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS8581.; Chaft J.E., Dahlberg S.E., Khullar O.V., Edelman M.J., Simone C.B., Heymach J. et al. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). J Clin Oncol. 2018;36(15_suppl):TPS8581-TPS8581. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8581.; Leighl N.B., Laurie S.A., Goss G.D., Hughes B.G.M., Stockler M., Tsao M.S. et al. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. J Thorac Oncol. 2022;17(3):434-445. https://doi.org/10.1016/j.jtho.2021.10.023.; Peters S., Spigel D., Ahn M., Tsuboi M., Chaft J., Harpole D. et al. MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery. J Thoracic Oncol. 2021;16(3):S258-S259. https://doi.org/10.1016/j.jtho.2021.01.376.; Garon E., Ardizzoni A., Barlesi F., Cho B.C., De Marchi P., Goto Y. et al. CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC. J Thoracic Oncol. 2019;14(10):S638-S639. https://doi.org/10.1016/j.jtho.2019.08.1346.; Liuzzo G., Ruggio A., Urbinati S. The CANTOS study. G Ital Cardiol (Rome). 2018;19(3):137-141. https://doi.org/10.1714/2883.29070.; Felip E., Altorki N., Zhou C., Csőszi T., Vynnychenko I., Goloborodko O. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344-1357. https://doi.org/10.1016/S0140-6736(21)02098-5.; Wakelee H.A., Altorki N.K., Zhou C., Csőszi T., Vynnychenko T.O., Goloborodko O. et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl): 8500-8500. https://doi.org/10.1200/JCO.2021.39.15_suppl.8500.; https://www.med-sovet.pro/jour/article/view/6910

الاتاحة: https://www.med-sovet.pro/jour/article/view/6910
https://doi.org/10.21518/2079-701X-2022-16-9-14-20

المصدر: Исследования и практика в медицине, Vol 8, Iss 2 (2021)

مصطلحات موضوعية: немелкоклеточный рак легкого, нмрл, лучевая терапия, химиотерапия, иммунотерапия, моноклональные антитела, ингибиторы pd, химиолучевая терапия, Medicine

وصف الملف: electronic resource

Relation: https://www.rpmj.ru/rpmj/article/view/662; https://doaj.org/toc/2409-2231; https://doaj.org/toc/2410-1893

URL الوصول: https://doaj.org/article/ccafd3a0875a4abdac44482eb7f51d28

المؤلفون: E. Smolenov I., G. Afonin V., V. Usachev S., D. Kudryavtsev D., I. Kolobaev V., S. Ivanov A., Е. Смоленов И., Г. Афонин В., В. Усачев С., Д. Кудрявцев Д., И. Колобаев В., С. Иванов А.

المصدر: Research and Practical Medicine Journal; Том 8, № 2 (2021); 109-123 ; Research'n Practical Medicine Journal; Том 8, № 2 (2021); 109-123 ; 2410-1893 ; 2409-2231 ; 10.17709/2410-1893-2021-8-2

مصطلحات موضوعية: non-small cell lung cancer, NSCLC, radiotherapy, chemotherapy, immunotherapy, monoclonal antibody, PD inhibitor, chemoradiotherapy, немелкоклеточный рак легкого, НМРЛ, лучевая терапия, химиотерапия, иммунотерапия, моноклональные антитела, ингибиторы PD, химиолучевая терапия

وصف الملف: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/727/421; Состояние онкологической помощи населению России в 2019 г. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой, М.: 2020, 236 с. Доступно по: https://glavonco.ru/cancer_register/Помощь%202019.pdf; Рагулин Ю.А. Сочетание иммунотерапии и лучевой терапии при немелкоклеточном раке легкого. Онкология. Журнал им. П.А.Герцена. 2018;7(5):90–96. https://doi.org/10.17116/onkolog2018705190; Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И.Переводчиковой, В.А.Горбуновой. M.: Практическая медицина, 2015, 686 с.; NCCN.org. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for non-small cell lung cancer V.4.2021. © National Comprehensive Cancer Network, Inc., 2021. Доступно по: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf; Рагулин Ю.А., Смоленов Е.И., Усачев В.С., Афонин Г.В. Таргетная терапия местно-распространенного немелкоклеточного рака легкого с EGFR – мутацией. Онкология. Журнал им. П.А.Герцена. 2016;5(2):48–53. https://doi.org/10.17116/onkolog20165248-53; Злокачественное новообразование бронхов и легкого. Ассоциация онкологов России. Клинические рекомендации. Под ред. А.Д. Каприна. М.: 2020, 90 с.; Родионов Е.О., Миллер С.В., Тузиков С.А., Ефтеев Л.А., Маркович В.А., Миллер Д.С. Иммунотерапия рецидивного немелкоклеточного рака легкого в первой линии. Медицинский Совет. 2019;(19):132–136. https://doi.org/10.21518/2079-701X-2019-19-132-136; Болотина Л.В., Каприн А.Д. Иммуноонкология: новые горизонты лекарственной терапии солидных опухолей. Онкология. Журнал им. П.А.Герцена. 2017;6(5):74–80. https://doi.org/10.17116/onkolog20176574-80; Сакаева Д.Д., Ручкин В.В., Гончарова О.В., Аббасова Р.Р., Муфазалов Ф.Ф. Дурвалумаб в терапии местно-распространенного немелкоклеточного рака легкого после химиолучевого лечения в реальной практике. Современная онкология. 2019;21(3);21–25. https://doi.org/10.26442/18151434.2019.3.190679; Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27. https://doi.org/10.1159/000386035; Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer. 1971 Jul;28(1):89–98. https://doi.org/10.1002/1097-0142(197107)28:13.0.co;2-q; Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, et al. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Apr 10;34(11):1223–1230. https://doi.org/10.1200/JCO.2015.63.0970; Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002 Nov;3(11):991–998. https://doi.org/10.1038/ni1102-991; Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015 Jun 18;6:e1792. https://doi.org/10.1038/cddis.2015.162; Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013 Apr;13(4):227–242. https://doi.org/10.1038/nri3405; Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975 Feb;53(1):27–42. https://doi.org/10.1038/icb.1975.3; Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009 May;229(1):12–26. https://doi.org/10.1111/j.1600-065X.2009.00770.x; Лактионов К.К., Саранцева К.А., Бредер В.В., Окружнова М.А., Перегудова М.В. Место иммуноонкологии в лечении немелкоклеточного рака легкого. Злокачественные опухоли. 2016;(3):17–24. https://doi.org/10.18027/2224-5057-2016-3-17-24; Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug;224:166–182. https://doi.org/10.1111/j.1600-065X.2008.00662.x; Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099–8103. https://doi.org/10.1073/pnas.94.15.8099; Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010 Aug;140(2):377–386. https://doi.org/10.1016/j.jtcvs.2009.12.054; Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010 Feb 20;28(6):928–935. https://doi.org/10.1200/JCO.2009.25.0928; O'Rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD002140. https://doi.org/10.1002/14651858.CD002140.pub3; Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181–2190. https://doi.org/10.1200/JCO.2009.26.2543; Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187–199. https://doi.org/10.1016/S1470-2045(14)71207-0; Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1325–1331. https://doi.org/10.1016/j.ijrobp.2012.11.011; Hepel JT, Leonard KL, Safran H, Ng T, Taber A, Khurshid H, et al. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study. Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1021–1027. https://doi.org/10.1016/j.ijrobp.2016.08.032; Higgins KA, Pillai RN, Chen Z, Tian S, Zhang C, Patel P, et al. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. J Thorac Oncol. 2017 Nov;12(11):1687–1695. https://doi.org/10.1016/j.jtho.2017.07.036; Kumar S, Feddock J, Li X, Shearer AJ, Hall L, Shelton BJ, et al. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):652–659. https://doi.org/10.1016/j.ijrobp.2017.07.036; Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1352–1358. https://doi.org/10.1016/j.ijrobp.2009.07.1751; Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010 Mar 17;303(11):1070–1076. https://doi.org/10.1001/jama.2010.261; Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016 Feb;40(1):25–37. https://doi.org/10.1016/j.currproblcancer.2015.10.001; Grass GD, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer. 2016 Feb;40(1):10–24. https://doi.org/10.1016/j.currproblcancer.2015.10.003; Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med. 2016 Mar;4(6):118. https://doi.org/10.21037/atm.2016.01.32; Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862–870. https://doi.org/10.1016/j.ijrobp.2003.09.012; Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park). 2008 Aug;22(9):1064–1084.; Daly ME, Monjazeb AM, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Dec;10(12):1685–1693. https://doi.org/10.1097/JTO.0000000000000686; Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014 Feb;124(2):687–695. https://doi.org/10.1172/JCI67313; Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Jul;12(7):1085–1097. https://doi.org/10.1016/j.jtho.2017.04.014; Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016 Jun 16;1(9):e87415. https://doi.org/10.1172/jci.insight.87415; Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014 Oct 1;74(19):5458–5468. https://doi.org/10.1158/0008-5472.CAN-14-1258; Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, et al. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clin Cancer Res. 2017 Sep 15;23(18):5514–5526. https://doi.org/10.1158/1078-0432.CCR-16-1673; Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 16;520(7547):373–377. https://doi.org/10.1038/nature14292; Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016 Nov 3;375(18):1749– 1755. https://doi.org/10.1056/NEJMoa1609214; Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2020 Feb;15(2):288–293. https://doi.org/10.1016/j.jtho.2019.10.002; Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 Jul;18(7):895–903. https://doi.org/10.1016/S1470-2045(17)30380-7; Durm GA, Jabbour SK, Althouse SK, Liu Z, Sadiq AA, Zon RT, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020 Oct 1;126(19):4353–4361. https://doi.org/10.1002/cncr.33083; Tamiya A, Tamiya M, Nakahama K, Taniguchi Y, Shiroyama T, Isa S-I, et al. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer. Anticancer Res. 2017 Sep;37(9):5199–5205. https://doi.org/10.21873/anticanres.11943; Kataoka Y, Ebi N, Fujimoto D, Hara S, Hirano K, Narabayashi T, et al. Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study. Ann Oncol. 2017 Jun 1;28(6):1402. https://doi.org/10.1093/annonc/mdx114; Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):344–351. https://doi.org/10.1016/j.ijrobp.2017.02.003; Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jan;15(1):59–68. https://doi.org/10.1016/S1470-2045(13)70510-2; Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015 Jun;26(6):1134–1142. https://doi.org/10.1093/annonc/mdv104; Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for nonsmall cell lung cancer. Eur J Cancer. 2015 Nov;51(16):2321–2329. https://doi.org/10.1016/j.ejca.2015.07.035; Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011 Nov 1;17(21):6847–6857. https://doi.org/10.1158/1078-0432.CCR-11-1385; Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generateabscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795–803. https://doi.org/10.1016/S1470-2045(15)00054-6; Fujimoto D, Uehara K, Sato Y, Sakanoue I, Ito M, Teraoka S, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep. 2017 Sep 12;7(1):11373. https://doi.org/10.1038/s41598-017-11949-9; Hecht M, Büttner-Herold M, Erlenbach-Wünsch K, Haderlein M, Croner R, Grützmann R, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016 Sep;65:52–60. https://doi.org/10.1016/j.ejca.2016.06.015; Lim SH, Hong M, Ahn S, Choi Y-L, Kim K-M, Oh D, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer. 2016 Jan;52:1–9. https://doi.org/10.1016/j.ejca.2015.09.019; Schoenhals JE, Seyedin SN, Anderson C, Brooks ED, Li YR, Younes AI, et al. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res. 2017 Apr;6(2):148–158. https://doi.org/10.21037/tlcr.2017.03.06; https://www.rpmj.ru/rpmj/article/view/727

الاتاحة: https://www.rpmj.ru/rpmj/article/view/727
https://doi.org/10.17709/2409-2231-2021-8-2-10

المصدر: Issledovaniâ i Praktika v Medicine, Vol 8, Iss 2 (2021)

مصطلحات موضوعية: немелкоклеточный рак легкого, нмрл, лучевая терапия, химиотерапия, иммунотерапия, моноклональные антитела, ингибиторы pd, химиолучевая терапия, Medicine

Relation: https://www.rpmj.ru/rpmj/article/view/662; https://doaj.org/toc/2409-2231; https://doaj.org/toc/2410-1893; https://doaj.org/article/ccafd3a0875a4abdac44482eb7f51d28

الاتاحة: https://doaj.org/article/ccafd3a0875a4abdac44482eb7f51d28

المؤلفون: A. Kolomeytseva A., A. Fedenko A., А. Коломейцева А., А. Феденко А.

المصدر: Siberian journal of oncology; Том 19, № 6 (2020); 119-125 ; Сибирский онкологический журнал; Том 19, № 6 (2020); 119-125 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-6

مصطلحات موضوعية: NSCLC, EGFR inhibitors, T790M mutation, gefitinib, erlotinib, afatinib, osimertinib, resistance, НМРЛ, ингибиторы EGFR, мутация T790M, гефитиниб, эрлотиниб, афатиниб, осимертиниб, резистентность

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1649/816; Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., Zhang S., Wang J., Zhou S., Ren S., Lu S., Zhang L., Hu C., Hu C., Luo Y., Chen L., Ye M., Huang J., Zhi X., Zhang Y., Xiu Q., Ma J., Zhang L., You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug; 12(8): 735–42. doi:10.1016/S1470-2045(11)70184-X.; Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., Porta R., Cobo M., Garrido P., Longo F., Moran T., Insa A., De Marinis F., Corre R., Bover I., Illiano A., Dansin E., de Castro J., Milella M., Reguart N., Altavilla G., Jimenez U., Provencio M., Moreno M.A., Terrasa J., Muñoz-Langa J., Valdivia J., Isla D., Domine M., Molinier O., Mazieres J., Baize N., Garcia-Campelo R., Robinet G., Rodriguez-Abreu D., Lopez-Vivanco G., Gebbia V., Ferrera-Delgado L., Bombaron P., Bernabe R., Bearz A., Artal A., Cortesi E., Rolfo C., Sanchez-Ronco M., Drozdowskyj A., Queralt C., de Aguirre I., Ramirez J.L., Sanchez J.J., Molina M.A., Taron M., Paz-Ares L.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar; 13(3): 239–46. doi:10.1016/S1470-2045(11)70393-X.; Wu Y.L., Zhou C., Liam C.K., Wu G., Liu X., Zhong Z., Lu S., Cheng Y., Han B., Chen L., Huang C., Qin S., Zhu Y., Pan H., Liang H., Li E., Jiang G., How S.H., Fernando M.C.L., Zhang Y., Xia F., Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015; 26(9): 1883–89. doi:10.1093/annonc/mdv270.; Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3; 361(10): 947–57. doi:10.1056/NEJMoa0810699.; Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T.; North-East Japan Study Group. Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24; 362(25): 2380–8. doi:10.1056/NEJMoa0909530.; Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., Geater S.L., Orlov S., Tsai C.M., Boyer M., Su W.C., Bennouna J., Kato T., Gorbunova V., Lee K.H., Shah R., Massey D., Zazulina V., Shahidi M., Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27): 3327–34. doi:10.1200/JCO.2012.44.2806.; Wu Y.L., Zhou C., Hu C.P., Feng J., Lu S., Huang Y., Li W., Hou M., Shi J.H., Lee K.Y., Xu C.R., Massey D., Kim M., Shi Y., Geater S.L. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb; 15(2): 213–22. doi:10.1016/S1470-2045(13)70604-1.; Pirker R., Pirker R., Buder A., Filipits M. Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3. Translational Cancer Res. 2017; 6: 265–9. doi:10.21037/tcr.2017.03.12.; Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar; 7(3): 169–81. doi:10.1038/nrc2088.; Spicer J.F., Rudman S.M. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol. 2010 Dec; 5(4): 245–55. doi:10.1007/s11523-010-0140-y.; Solca F., Dahl G., Zoephel A., Bader G., Sanderson M., Klein C., Kraemer O., Himmelsbach F., Haaksma E., Adolf G.R. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012 Nov; 343(2): 342–50. doi:10.1124/jpet.112.197756.; Modjtahedi H., Cho B.C., Michel M.C., Solca F. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jun; 387(6): 505–21. doi:10.1007/s00210-014-0967-3.; Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., Padera R.F., Shapiro G.I., Baum A., Himmelsbach F., Rettig W.J., Meyerson M., Solca F., Greulich H., Wong K.K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7; 27(34): 4702–11. doi:10.1038/onc.2008.109.; Yang J.C., Wu Y.L., Schuler M., Sebastian M., Popat S., Yamamoto N., Zhou C., Hu C.P., O'Byrne K., Feng J., Lu S., Huang Y., Geater S.L., Lee K.Y., Tsai C.M., Gorbunova V., Hirsh V., Bennouna J., Orlov S., Mok T., Boyer M., Su W.C., Lee K.H., Kato T., Massey D., Shahidi M., Zazulina V., Sequist L.V. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16(2): 141–51. doi:10.1016/S1470-2045(14)71173-8.; Schuler M., Wu Y.L., Hirsh V., O'Byrne K., Yamamoto N., Mok T., Popat S., Sequist L.V., Massey D., Zazulina V., Yang J.C. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016 Mar; 11(3): 380–90. doi:10.1016/j.jtho.2015.11.014.; Park K., Tan E.H., O'Byrne K., Zhang L., Boyer M., Mok T., Hirsh V., Yang J.C., Lee K.H., Lu S., Shi Y., Kim S.W., Laskin J., Kim D.W., Arvis C.D., Kölbeck K., Laurie S.A., Tsai C.M., Shahidi M., Kim M., Massey D., Zazulina V., Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUXLung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17(5): 577–89. doi:10.1016/S1470-2045(16)30033-X.; Yang J.C., Sequist L.V., Geater S.L., Tsai C.M., Mok T.S., Schuler M., Yamamoto N., Yu C.J., Ou S.H., Zhou C., Massey D., Zazulina V., Wu Y.L. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul; 16(7): 830–8. doi:10.1016/S1470-2045(15)00026-1.; Hirano T., Yasuda H., Tani T., Hamamoto J., Oashi A., Ishioka K., Arai D., Nukaga S., Miyawaki M., Kawada I., Naoki K., Costa D.B., Kobayashi S.S., Betsuyaku T., Soejima K. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015 Nov 17; 6(36): 38789–803. doi:10.18632/oncotarget.5887.; Mok T.S., Wu Y.-L., Ahn M.-J., Garassino M.C., Kim H.R., Ramalingam S.S., Shepherd F.A., He Y., Akamatsu H., Theelen W.S., Lee C.K., Sebastian M., Templeton A., Mann H., Marotti M., Ghiorghiu S., Papadimitrakopoulou V.A.; AURA3 Investigators. Osimertinib or PlatinumPemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16; 376(7): 629–640. doi:10.1056/NEJMoa1612674.; Soria J.C., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee K.H., Dechaphunkul A., Imamura F., Nogami N., Kurata T., Okamoto I., Zhou C., Cho B.C., Cheng Y., Cho E.K., Voon P.J., Planchard D., Su W.C., Gray J.E., Lee S.M., Hodge R., Marotti M., Rukazenkov Y., Ramalingam S.S.; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan 11; 378(2): 113–125. doi:10.1056/NEJMoa1713137.; Ohe Y., Imamura F., Nogami N., Okamoto I., Kurata T., Kato T., Sugawara S., Ramalingam S.S., Uchida H., Hodge R., Vowler S.L., Walding A., Nakagawa K. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol. 2019 Jan 1; 49(1): 29–36. doi:10.1093/jjco/hyy179.; Cho J.H., Lim S.H., An H.J., Kim K.H., Park K.U., Kang E.J., Choi Y.H., Ahn M.S., Lee M.H., Sun J.M., Lee S.H., Ahn J.S., Park K., Ahn M.J. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol. 2020 Feb 10; 38(5): 488–495. doi:10.1200/JCO.19.00931.; Gerlinger M., Rowan A.J., Horswell S., Math M., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012 Mar 8; 366(10): 883–892. doi:10.1056/NEJMoa1113205.; Murtaza M., Dawson S.J., Tsui D.W., Gale D., Forshew T., Piskorz A.M., Parkinson C., Chin S.F., Kingsbury Z., Wong A.S., Marass F., Humphray S., Hadfield J., Bentley D., Chin T.M., Brenton J.D., Caldas C., Rosenfeld N. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497(7447): 108–12. doi:10.1038/nature12065.; Arcila M.E., Oxnard G.R., Nafa K., Riely G.J., Solomon S.B., Zakowski M.F., Kris M.G., Pao W., Miller V.A., Ladanyi M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011 Mar 1; 17(5): 1169–80. doi:10.1158/1078-0432.CCR-10-2277.; Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., Bergethon K., Shaw A.T., Gettinger S., Cosper A.K., Akhavanfard S., Heist R.S., Temel J., Christensen J.G., Wain J.C., Lynch T.J., Vernovsky K., Mark E.J., Lanuti M., Iafrate A.J., Mino-Kenudson M., Engelman J.A. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75): 75ra26. doi:10.1126/scitranslmed.3002003.; Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., Kris M.G., Miller V.A., Ladanyi M., Riely G.J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013 Apr 15; 19(8): 2240–7. doi:10.1158/1078-0432.CCR-12-2246.; Yang J.C., Ahn M.J., Kim D.W., Ramalingam S.S., Sequist L.V., Su W.C., Kim S.W., Kim J.H., Planchard D., Felip E., Blackhall F., Haggstrom D., Yoh K., Novello S., Gold K., Hirashima T., Lin C.C., Mann H., Cantarini M., Ghiorghiu S., Jänne P.A. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20; 35(12): 1288–1296. doi:10.1200/JCO.2016.70.3223.; Ahn M.J., Tsai C.M., Shepherd F.A., Bazhenova L., Sequist L.V., Hida T., Yang J.C.H., Ramalingam S.S., Mitsudomi T., Jänne P.A., Mann H., Cantarini M., Goss G. Osimertinib in patients with T790M mutationpositive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 Mar 15; 125(6): 892–901. doi:10.1002/cncr.31891.; Le X., Puri S., Negrao M.V., Nilsson M.B., Robichaux J., Boyle T., Hicks J.K., Lovinger K.L., Roarty E., Rinsurongkawong W., Tang M., Sun H., Elamin Y, Lacerda L.C., Lewis J., Roth J.A., Swisher S.G., Lee J.J., William W.N.Jr., Glisson B.S., Zhang J., Papadimitrakopoulou V.A., Gray J.E., Heymach J.V. Landscape of EGFR-Dependent and Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res. 2018 Dec 15; 24(24): 6195–6203. doi:10.1158/1078-0432.CCR-18-1542.; Piotrowska Z., Thress K., Mooradian M.J., Heist R.S., Azzoli C.G., Temel J.S., Evans T. MET amplification (amp) as a resistance mechanism to osimertinib. Clin. Oncol. 2017; 35: 9020.; Tan C.S., Kumarakulasinghe N.B., Huang Y.Q., Ang Y.L.E., Choo J.R., Goh B.C., Soo R.A. Third generation EGFR TKIs: current data and future directions. Mol Cancer. 2018 Feb 19; 17(1): 29. doi:10.1186/s12943-018-0778-0.; Thress K.S., Paweletz C.P., Felip E., Cho B.C., Stetson D., Dougherty B., Lai Z., Markovets A., Vivancos A., Kuang Y., Ercan D., Matthews S.E., Cantarini M., Barrett J.C., Jänne P.A., Oxnard G.R. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun; 21(6): 560–2. doi:10.1038/nm.3854.; Oxnard G.R., Hu Y., Mileham K.F., Husain H., Costa D.B., Tracy P., Feeney N., Sholl L.M., Dahlberg S.E., Redig A.J., Kwiatkowski D.J., Rabin M.S., Paweletz C.P., Thress K.S., Jänne P.A. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 Nov 1; 4(11): 1527–1534. doi:10.1001/jamaoncol.2018.2969.; Yang Z., Yang N., Ou Q., Xiang Y., Jiang T., Wu X., Bao H., Tong X., Wang X., Shao Y.W., Liu Y., Wang Y., Zhou C. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2018 Jul 1; 24(13): 3097–3107. doi:10.1158/1078-0432.CCR-17-2310.; Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol. 2018; 14(11): 1117–32. doi:10.2217/fon-2017-0636.; Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol. 2018 Jan 22; 10: 1758834017753338. doi:10.1177/1758834017753338.; Reck M., Mok T.S.K., Nishio M., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., Thomas C.A., Barlesi F., Finley G., Lee A., Coleman S., Deng Y., Kowanetz M., Shankar G., Lin W., Socinski M.A.; IMpower150 Study Group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open- label phase 3 trial. Lancet Respir Med. 2019 May; 7(5): 387–401. doi:10.1016/S2213-2600(19)30084-0.; Sequist L.V., Wu Y.L., Schuler M. Subsequent therapies post-afatinib among patients with EGFRmutation-positive NSCLC in LUX-Lung (LL) 3, 6 and 7. Ann Oncol. 2017; 28(suppl 2): doi:10.1093/annonc/mdx380.051.; Hochmair M.J., Morabito A., Hao D., Yang C.T., Soo R.A., Yang J.C., Gucalp R., Halmos B., Wang L., Golembesky A., Märten A., Cufer T. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018 Nov; 14(27): 2861–2874. doi:10.2217/fon-2018-0711.; Hochmair M.J., Morabito A., Hao D., Yang C.T., Soo R.A., Yang J.C., Gucalp R., Halmos B., Wang L., Märten A., Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019 Sep; 15(25): 2905–2914. doi:10.2217/fon-2019-0346.; Kohsaka S., Petronczki M., Solca F., Maemondo M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol. 2019 Feb; 15(6): 637–52. doi:10.2217/fon-2018-0736.; Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) [Internet]. URL: https://clinicaltrials.gov/ct2/show/NCT02856893 (cited 14.11.2019).; https://www.siboncoj.ru/jour/article/view/1649

الاتاحة: https://www.siboncoj.ru/jour/article/view/1649
https://doi.org/10.21294/1814-4861-2020-19-6-119-125

المؤلفون: K. Laktionov K., D. Yudin I., V. Breder V., E. Reutova V., K. Laktionov P., D. Marinov T., D. Peregudov A., M. Ardzinba S., К. Лактионов К., Д. Юдин И., В. Бредер В., Е. Реутова В., К. Лактионов П., Д. Маринов Т., Д. Перегудов А., М. Ардзинба С.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2019); 110-114 ; Медицинский Совет; № 10 (2019); 110-114 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-10

مصطلحات موضوعية: NSCLC, EGFR, tyrosine kinase inhibitors, integrated chemotherapy, НМРЛ, ингибиторы тирозинкиназы, интегрированная химиотерапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/3060/2984; Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13(3):239-246.; Sequist L.V., Yang J.C., Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334.; Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.; Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis. PLOS ONE. 2013 November 8;8(Issue 11):e79000. www.plosone.org; Kanda S., Horinouchi H., Fujiwara Y., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Kubota K., Tamura T., Ohe Y. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 2015 Sep;89(3):287-93.; Soria J.-C., Ohe Y., Vansteenkiste J. et al. FLAURA Investigators. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;278(2):113-125.; Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932–20937.; Engleman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O. et al. MET amplification leads to gefitinib resistance in lung cancer by activation ERBB3 signaling. Science. 2007;316:1039–1043.; Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247.; Soria J.C., Wu Y.L., Nakagawa K. et al. Gefi tinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-smallcell lung cancer after progression on first-line gefi tinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–98.; Saito H., Fukuhara T. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous nonsmall- cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625–35.; Nakamura A., Inoue A. et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Journal of Clinical Oncology. 2018 May 20;36(15_suppl):9005-9005.; https://www.med-sovet.pro/jour/article/view/3060

الاتاحة: https://www.med-sovet.pro/jour/article/view/3060
https://doi.org/10.21518/2079-701X-2019-10-110-114

المؤلفون: N. A. Meshcheryakova, M. B. Dolgushin, T. N. Borisova, M. M. Davydov, K. K. Laktionov, Н. А. Мещерякова, М. Б. Долгушин, Т. Н. Борисова, М. М. Давыдов, К. К. Лактионов

المصدر: Medical Visualization; № 1 (2017); 53-56 ; Медицинская визуализация; № 1 (2017); 53-56 ; 2408-9516 ; 1607-0763

مصطلحات موضوعية: химиолучевая терапия, 18F-FDG, 18F-FLT, NSCLC, chemoirradiation, 18F-ФДГ, 18F-фтортимидин, НМРЛ

وصف الملف: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/375/363; Lardinois D., Weder W., Hany T.F. et al. Staging of nonsmall-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 2003; 348: 2500–2507.; MacManus M., Nestle U., Rosenzweig K.E. et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother. Oncol. 2009; 91: 85–94.; Van Elmpt W., De Ruysscher D., van der Salm A. et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother. Oncol. 2012; 104 (1): 67–71.; Mac Manus M., Hicks R.J., Matthews J. et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer. 2005; 49: 95–108.; Van Baardwijk A., Bosmans G., Dekker A. et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy: a prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother. Oncol. 2007; 82:145–152.; Vera P., Bohn P., Edet-Sanson A. et al. Simultaneous positron emission tomography (PET) assessment of metabolism with 18F-fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F- fluoro-thymidine (FLT), and hypoxia with 18fluoro-miso- nidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother. Oncol. 2011; 98: 109–116.; Kenny L.M., Aboagye E.O., Price P.M. Positron emission tomography imaging of cell proliferation in oncology. Clin. Oncol. (R. Coll. Radiol.). 2004; 16: 176–185.; Everitt S.J., Ball D.L. Hicks R.J. et al. Differential 18F-FDG and 18F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. J. Nucl. Med. 2014; 55: 1069–1074.; Barwick T., Bencherif B., Mountz J.M., Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl. Med. Commun. 2009; 30: 908–917.; Buck A.K., Herrmann K., Shen C. et al. Molecular imaging of proliferation in vivo: positron emission tomography with [18F] fluorothymidine. Methods. 2009; 48: 205–215.; Wahl R.L., Jacene H., Kasamon Y. et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50 (1): 122S–150S.; Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009; 45 (2): 228–247.; https://medvis.vidar.ru/jour/article/view/375

الاتاحة: https://medvis.vidar.ru/jour/article/view/375
https://doi.org/10.24835/1607-0763-2017-1-53-56

المؤلفون: K. S. TITOV, O. Y. MIKHEEVA, A. M. KAZAKOV, A. V. EGOROVA, К. С. ТИТОВ, О. Ю. МИХЕЕВА, А. М. КАЗАКОВ, А. В. ЕГОРОВА

المصدر: Malignant tumours; № 3 (2016); 25-31 ; Злокачественные опухоли; № 3 (2016); 25-31 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: НМРЛ, metastasis, surgery, ИТК

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/257/229; Torre L.A. Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemak A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar; 65(2):87–108.; Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199–6206.; Thompson J.F., Morton D.L., Balch C.M., et al. Surgical excision of distant melanoma metastases. In: Balch CMea., editor. Cutaneous Melanoma. St. Louis: Quality Medical Publishing; 2009.; Михайлова И. Н., Шубина И. Ж., Титов К. С., Мамедова Л. Т. Химиоиммунотерапия онкологических больных // Вопросы онкологии. – 2015. –№ 5. – С. 716–718. Mikhaylova I. N., Choubina I. Zh., Titov K. S., Mamedova of L. T. Himioimmunoterapiya of oncological patients//Questions of oncology. – 2015. –№ 5. – Page 716–718.; Демидов Л. В., Булавина И. С., Гладков О. А., Зинькевич М. В., Марочко А. Ю., Новик А. В. и соавт. Практические рекомендации по лекарственному лечению меланомы кожи // Злокачественные опухоли. – 2015. – № 4, спецвыпуск. – С. 162–170. Demidov L. V., Bulavina I. S., Gladkov O. A., Zinkevich M. V., Marochko A. Yu., Novick A. V. et al. Practical recommendations about medicinal treatment of a melanoma of skin//Malignant tumors. – 2015. – No. 4, special issue. – Page 162–170.; Batus M., Waheed S., Ruby C., Petersen L., Bines S.D., Kaufman H.L.: Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol 14: 179–194, 2013.; Karakousis C. Et al. Local recurrence in malignant melanoma: Long-term results of the multi institutional randomized surgical trial // Ann. Surg. Oncol. – 1996. – Vol.3. – P. 440.; Anna M. Leung, MD, Surgical Oncology Fellow, Danielle M. Hari, MD. Surgery for Distant Melanoma Metastasis. Cancer J. 2012 Mar; 18(2): 176–184.; Clawson G.A., Kimchi E., Patrick S.D., Xin P., Harouaka R., Zheng S., Berg A., Schell T., Staveley-O’Carroll K.F., Neves R.I., Mosca P.J., Thiboutot D. Circulating tumor cells in melanoma patients. PLoS One. 2012; 7(7): e41052.; Wasif N., Bagaria S.P., Ray P., Morton D.L. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011 Aug 1;104(2):111–5.; Younes R., Abrao F.C., Gross J. Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res. 2013 Aug; 23 (4):307–11.; Neuman H.B., Patel ., Hanlon C., Wolchok J.D., Houghton A.N., Coit D.G. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007 Oct; 14 (10):2847–53.; Doussot A., Nardin C., Takaki H., Litchman T.D., D’Angelica M.I., Jarnagin W.R., Postow M.A., Erinjeri J.P., Kingham T.P. Liver resection and ablation for metastatic melanoma: A single center experience. J Surg Oncol. 2015 Jun;111(8): р. 962–8.; Nabil Wasif, MD, Sanjay P Bagaria, MD, Partha Ray, MD, and Donald L Morton, MD, FACS. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. Surg Oncol. Author manuscript; available in PMC2012 Aug 1. 15. Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001; 136:950–955.; Bo ena Cybulska-Stopa, Marta Skoczek, Marek Ziobro, Tomasz witaj, S awomir Falkowski, Tadeusz Morysi ski, Marcin Hetna , Ida Cedrych, and Piotr Rutkowski. Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Contemp Oncol (Pozn). 2013; 16(6): 532–545.; Петроченко Н. С. «Изолированная перфузия конечностей с гипертермией у больных с местно-диссеминированной меланомой кожи и саркомами мягких тканей». Москва. – дисс. к. м.н., 2015. Petrochenko N. S. «The isolated perfusion of extremities with a hyperthermia at patients with a local disseminirovannoy a melanoma of skin and sarcomas of soft fabrics». Moscow. – yew. Candidates of Medical Science., 2015.; Jason J. Lukecorresponding authora and F. Stephen Hodi. Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAFMutant Malignant Melanoma. Oncologist. 2013 Jun; 18(6): р. 717–725.; Eggermont A.M., Chiarion-Sileni V., Grob J.J., Dummer R., Wolchok J.D., Schmidt H., Hamid O. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 May;16 (5): р. 522–30.; Shachar Laks, Kevin A Brueske, and Eddy C Hsueh. Neoadjuvant treatment of melanoma: case reports and review. Exp Hematol Oncol. 2013; 2:30.; Baker J.J., Stitzenberg K.B., Collichio F.A., Meyers M.O., Ollila D.W. Systematic review: surgery for patients with metastatic melanoma during active treatment with ipilimumab. Am Surg. 2014 Aug; 80(8):805–10.; Fadaki N., Cardona-Huerta S., Martineau L., Thummala S., Cheng S.T., Bunker S.R. et al. Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep. 2012; р.22.; Koers K., Francken A.B., Haanen J.B., Woerdeman L.A., von der Hage J.A. Vemurafenib as eoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol. 2013;31(16): e251–3.; Shenoy S., Cassim R. Metastatic melanoma to the gastrointestinal tract: role of surgery as palliative treatment. W V Med J. 2013; 109(January–February (1)): р. 30–33.; Szynglarewicz B., Ekiert M., Forgacz J., Halon A., Skalik R., Matkowski R. The role of surgery in the treatment of colorectal metastases from primary skin melanoma. Colorectal Dis. 2012;14(June (6)): р. 305–e311.; Angelica Conversano, Simona Macina, Rocco Indellicato, Domenico Lacavalla, and Dario D’Abbicco. Gastrointestinal bleeding as presentation of small bowel metastases of malignant melanoma: Is surgery a good choice? Int J Surg Case Rep. 2014; 5(10): р. 774–778.; https://www.malignanttumors.org/jour/article/view/257

الاتاحة: https://www.malignanttumors.org/jour/article/view/257
https://doi.org/10.18027/2224-5057-2016-3-25-31

المؤلفون: D. D. SAKAEVA, M. G. GORDIEV, Д. Д. САКАЕВА, М. Г. ГОРДИЕВ

المصدر: Malignant tumours; № 3 (2016); 54-59 ; Злокачественные опухоли; № 3 (2016); 54-59 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: НМРЛ, TKIs, NSCLC, ИТК

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/261/233; D.S. Salomon, R. Brandt, F. Ciardiello, N. Normanno «Epidermal growth factor-related peptides and their receptors in human malignancies», Crit. Rev. Oncol. Hematol., 19 (1995), pp. 183–232.; Oda K., Matsuoka Y., Funahashi A., Kitano H. (2005). «A comprehensive pathway map of epidermal growth factor receptor signaling». Mol. Syst. Biol. 1 (1): 2005.0010.; Gazdar A. F. et al. «Inhibition of EGFR Signaling: All Mutations Are Not Created Equal Trends» Mol Med 2004; 10: 481–486.; Sharma S. et al. «Epidermal growth factor receptor mutations in lung cancer». Nat Rev Cancer 2007; 7:169–81.; В.М. Моисеенко, С. А. Проценко, И. И. Семенов. Современная Онкология № 1, том 12, 2010, 60–66. V. M. Moiseenko, S. A. Protsenko, I. I. Semenov, Sovremennaya Onkologiya №1, vol 12, 2010,60–66.; Практические рекомендации по лечению злокачественных опухолей. Портал Российского общества клинической онкологии rosoncoweb.ru [Электронный ресурс], 06.06.16, URL: http://www.rosoncoweb.ru/standarts/RUSSCO/01.pdf Prakticheskie rekommendacii po lecheniyu zlokachestvennyh opukholei. Portal Rossiiskogo obschestva klinicheskoy onkologii rosoncoweb.ru. [Electronic resource], 06.06.16, URL: http://www.rosoncoweb.ru/standarts/RUSSCO/01.pdf; M. Reck, S. Popat, N. Reinmuth, D. De Ruysscher, K. M. Kerr and S. Peters, «Metastatic non-small-cell lung cancer (NSCLC): SMO Clinical Practice Guidelines for diagnosis, treatment and follow-up». Ann Oncol (2014) 25 (suppl 3): iii27-iii39.; Masters et al. «Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update». JCO August 31, 2015, 1–30.; NCCN Guidelines. Портал национальной всеобщей онкологической сети nccn.org. [Электронный ресурс], 06.06.16, URL: http://www.nccn.org/professionals/physician_ gls/pdf/nscl.pdf NCCN Guidelines. Portal nacional’noj vseobshhej onkologicheskoj seti nccn.org. [Jelektronnyj resurs], 06.06.16, URL: http://www.nccn.org/professionals/physician_gls/pdf/ nscl.pdf; Tony S. Mok, Yi-Long Wu, Sumitra Thongprasert, Chih- Hsin Yang, Da-Tong Chu, Nagahiro Saijo, et al. «Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma», N Engl J Med 2009; 361:947–957.; Han J. Y., Park K., Kim S. W. et al. First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30:1122–8.; Maemondo M., Inoue A., Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362:2380–8.; Mitsudomi T., Morita S., Yatabe Y. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WTJOG 3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11:121–8.; Zhou C., Wu Y. L., Chen G. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG‑0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2011; 12:735–42.; Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 13:239–46.; Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Ronald Feld, Charles Butts et al. First- Line Erlotinib Followedby Second-Line CisplatinGemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial J Clinical Oncol. Vol 30 Num 24 2012:3002–3011.; Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O’Byrne et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 2013; Vol 31 Num 27:3327–3334; Wu Y.L., Zhou C., Hu C.P. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX–Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213–222.; Сервис Национального Института Здоровья США// Портал ClinicalTrials.gov [Электронный ресурс], 20.10.15. URL: https://clinicaltrials.gov/ct2/results? term=chemotherapy+and+ TKI+NSCLC&Search=Search Servis Nacional’nogo Instituta Zdorov’ja SShA// Portal ClinicalTrials.gov [Jelektronnyj resurs], 20.10.15. URL: https://clinicaltrials.gov/ct2/results?term= chemotherapy+and+ TKI+NSCLC&Search=Search 20. Wu Y. L., Lee J. S., Thongprasert S., Yu C. J., Zhang L., Ladrera G. et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT‑2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul; 14(8):777–86.; Kanda S. et al. Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced nonsmall cell lung cancer haboring an epidermal growth factor receptor activating mutation. ASCO 2013, abs 8064 J Clin Oncol 31, 2013 (suppl; abstr 8064).; S. Sugawara, S. Oizumi, K. Minato et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Ann Oncol (2015) 26 (5): 888–894.; O.Ishimoto, S. Oizumi, K. Minato et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/ TCOG0902. Annals of Oncology 25 (Supplement 4): iv426– iv470, 2014.; Ying Cheng, Haruyasu Murakami, Pan-Chyr Yang, Jianxing He, Kazuhiko Nakagawa et al. Randomized Trial of Gefitinib with and without Pemetrexed as First-Line Therapy in East- Asian Patients with Advanced NS NSCLC with EGFR Mutations. Journal of Thoracic Oncology, Vol 10, Sup 2, 2015, S206 (ORAL 17.02).; D’Angelo S.P. et al. Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers J Thorac Oncol. 2012; 7: 1815–1822.; Karen Kelly, Nasser K. Altorki, Wilfried E. E. Eberhardt, Mary E. R. O’Brien et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. V. 33, Num. 34, 2015: 1–8; Сервис Национального Института Здоровья США// Портал ClinicalTrials.gov [Электронный ресурс], 07.06.16. URL: https://clinicaltrials.gov/ct2/show/ NCT02511106? term=ADAURA&rank=1 Servis Nacional’nogo Instituta Zdorov’ja SShA// Portal ClinicalTrials.gov [Jelektronnyj resurs], 07.06.16. URL: https://clinicaltrials.gov/ct2/show/ NCT02511106?term=ADAURA&rank=1; Pasi A. J nne, James Chih-Hsin Yang, Dong-Wan Kim, David Planchard, Yuichiro Ohe, Suresh S. et al. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer, N Engl J Med 2015; 372:1689–1699.; Catherine A. Eberlein, Daniel Stetson, Aleksandra A. Markovets, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res; 75(12) June 15, 2015, 2489–2500.; https://www.malignanttumors.org/jour/article/view/261

الاتاحة: https://www.malignanttumors.org/jour/article/view/261
https://doi.org/10.18027/2224-5057-2016-3-54-59

المؤلفون: S. V. Orlov, S. N. Fogt, M. S. Shustova

المصدر: Issledovaniâ i Praktika v Medicine, Vol 2, Iss 4, Pp 132-136 (2016)

مصطلحات موضوعية: бевацизумаб, биоаналог, «авегра®», рак легкого, нмрл, антиангиогенные препараты, блокада vegf, vascular endothelial growth factor, Medicine

Relation: https://www.rpmj.ru/rpmj/article/view/113; https://doaj.org/toc/2410-1893; https://doaj.org/article/0a6ac126651e44c3973c599744998329

الاتاحة: https://doi.org/10.17709/2409-2231-2015-2-4-132-136
https://doaj.org/article/0a6ac126651e44c3973c599744998329

المؤلفون: Сакаева Дина Дамировна, Гордиев Марат Гордиевич

مصطلحات موضوعية: EGFR мутация, ИТК, НМРЛ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/retseptor-epidermalnogo-faktora-rosta-kak-mishen-molekulyarno-napravlennoy-terapii-u-nepredlechennyh-patsientov-s-nemelkokletochnym
http://cyberleninka.ru/article_covers/16943545.png

المؤلفون: Лактионов Константин Константинович, Саранцева Ксения Андреевна, Бредер Валерий Владимирович, Окружнова Мария Александровна, Перегудова Марина Валерьевна

مصطلحات موضوعية: НМРЛ, иммуноонкология, ингибиторы контрольных точек

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/mesto-immunoonkologii-v-lechenii-nemelkokletochnogo-raka-legkogo
http://cyberleninka.ru/article_covers/16943540.png

المؤلفون: Титов Константин Сергеевич, Михеева Ольга Юрьевна, Казаков Алексей Михайлович, Егорова Ангелина Владимировна

مصطلحات موضوعية: EGFR мутация, ИТК, НМРЛ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/rol-hirurgii-v-lechenii-otdalennyh-metastazov-melanomy-kozhi
http://cyberleninka.ru/article_covers/16943541.png

المؤلفون: МАМИЧЕВ ИВАН АНДРЕЕВИЧ, БОГУШ Т.А., ДУДКО Е.А., РЯБИНИНА О.М., ГРИШАНИНА А.Н., КИРСАНОВ В.Ю., ПОЛОЦКИЙ Б.Е., ДАВЫДОВ М.М.

مصطلحات موضوعية: НЕМЕЛКОКЛЕТОЧНЫЙ РАК ЛЕГКОГО (НМРЛ),НОРМАЛЬНАЯ ТКАНЬ ЛЕГКОГО,БЕТА-III ТУБУЛИН (TUBB3),ПРОТОЧНАЯ ЦИТОФЛУОРИМЕТРИЯ,NON-SMALL CELL LUNG CARCINOMA (NSCLC),NORMAL LUNG TISSUE,CLASS IIIBETA-TUBULIN (TUBB3),FLOW CYTOMETRY

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/immunofluorestsentnyy-analiz-ekspressii-beta-iii-tubulina-v-opuholevoy-i-okruzhayuschey-normalnoy-tkani-patsientov-s-nemelkokletochnym
http://cyberleninka.ru/article_covers/16789964.png

المؤلفون: БАХТИН А.В., КИТ О.И., НОВИКОВА И.А., ЗЛАТНИК Е.Ю., ИСАЕВА Р.Г., СЕЛЮТИНА О.Н., ШУЛЬГИНА О.Г.

مصطلحات موضوعية: МЕЛКОКЛЕТОЧНЫЙ РАК ЛЕГКОГО (МРЛ), SMALL CELL LUNG CANCER (SCLC), НЕМЕЛКОКЛЕТОЧНЫЙ РАК ЛЕГКОГО (НМРЛ), NON-SMALL CELL LUNG CANCER (NSCLC), ЦИРКУЛИРУЮЩИЕ ОПУХОЛЕВЫЕ КЛЕТКИ (ЦОК), CIRCULATING TUMOR CELLS (CTCS), ИММУНОКОМПЕТЕНТНЫЕ КЛЕТКИ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/detektsiya-tsirkuliruyuschih-v-krovi-opuholevyh-kletok-i-ih-vzaimootnoshenie-s-immunokompetentnymi-kletkami-u-bolnyh-generalizovannymi
http://cyberleninka.ru/article_covers/15948715.png

المؤلفون: Орлов Сергей Владимирович, Фогт Сергей Николаевич, Шустова Мария Станиславовна

مصطلحات موضوعية: бевацизумаб, биоаналог, «Авегра®», рак легкого, НМРЛ, антиангиогенные препараты, блокада VEGF, Vascular endothelial growth factor

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/uspeshnaya-registratsiya-otechestvennogo-bioanaloga-bevatsizumaba-novye-vozmozhnosti-effektivnoy-terapii-bolnyh-neploskokletochnym
http://cyberleninka.ru/article_covers/16071351.png